IL-2 infusion abrogates humoral immune responses in humans
- 1 March 1992
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 87 (3) , 493-498
- https://doi.org/10.1111/j.1365-2249.1992.tb03025.x
Abstract
SUMMARY: Although IL-2 infusion enhances cell-mediated cytotoxicity in patients with neoplastic disease, administration is paradoxically associated with a modest fall in total serum IgG and an increased risk of infection. We now show that the adverse effects of IL-2 infusion on the humoral immune system are substantial. Although IL-2 induces the B cell growth and differentiating factors IL-4 and IL-6, infusion abrogates primary antibody responses entirely and reduces secondary antibody responses 50-fold following antigen challenge. There is no evidence of the generation of cells with suppressive activity on B cells but IL-2 increases the ratio of circulating virgin: memory cells. These results may help to explain the increased rate of bacterial infection in patients receiving IL-2. As IL-2 plays a central role in the generation of an immune response, the finding that it is also sufficiently immunosuppressive to inhibit primary- and secondary-type antibody responses suggests that exploration of the underlying mechanisms may provide insights into immune system homeostasis and may offer new approaches to therapeutic immunosuppression.Keywords
This publication has 30 references indexed in Scilit:
- The development of primed/memory CD8+ lymphocytes in vitro and in rejecting kidneys after transplantationClinical and Experimental Immunology, 1990
- An Acquired Chemotactic Defect in Neutrophils from Patients Receiving Interleukin-2 ImmunotherapyNew England Journal of Medicine, 1990
- Lymphokine regulation of CD45R expression on human T cell clones.The Journal of Experimental Medicine, 1989
- Interleukin (IL) 4 counteracts the helper effect of IL 2 on antigen‐activated human B cellsEuropean Journal of Immunology, 1989
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Production of hybridoma growth factor by human monocytesEuropean Journal of Immunology, 1987
- TRANSFER OF A FUNCTIONING HUMORAL IMMUNE SYSTEM IN TRANSPLANTATION OF T-LYMPHOCYTE-DEPLETED BONE MARROWThe Lancet, 1986
- T cell help in human antigen‐specific antibody responses can be replaced by interleukin 2European Journal of Immunology, 1986
- Expression of interleukin 2 receptors on activated human B cells.The Journal of Experimental Medicine, 1984
- Interleukin 2 induces antigen-reactive T cell lines to secrete BCGF-I.The Journal of Experimental Medicine, 1983